HER2-Positive Breast Cancer Trial Reports 92% Survival in Chemo-Free Patients; Proof Pending
· techtimes.com · popularity 21/100 · 0 similar stories today · Cancer & Oncology (Health & Life Sciences)
Read the original at techtimes.com →
Summary
HER2-positive breast cancer chemotherapy can be safely omitted in about 30% of patients, five-year PHERGain trial data published in Nature Medicine show, with 86 chemo-free patients achieving 92.4% invasive disease-free survival over 5.6 years -- but the non-comparative trial design stops short of formally proving de-escalation is safe.
Found in: Tech Times. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 2.